Oxamate targeting aggressive cancers with special emphasis to brain tumors

Area of Science:

• Oncology
• Biochemistry
• Mitochondrial Biology

Background:

• Cancer, a leading cause of mortality, includes aggressive brain tumors with poor prognoses.
• Malignant cells often exhibit mitochondrial dysfunction, relying on anaerobic glycolysis and increased Lactate Dehydrogenase-A (LDHA) expression.
• Developing novel strategies for refractory cancers and brain tumors is crucial.

Purpose of the Study:

• To investigate the potential of oxamate, an LDHA inhibitor, as a therapeutic agent for aggressive cancers, especially brain tumors.
• To explore the synergistic effects of oxamate in combination with phenformin.
• To address the clinical limitations of oxamate, such as its low cell membrane penetrance.

Main Methods:

• Preclinical studies evaluating oxamate's efficacy against invasive pituitary adenomas, medulloblastomas, and glioblastomas.
• Assessment of oxamate's impact on temozolomide and radiotherapy sensitivity in glioblastomas.
• Investigation of oxamate analogs targeting LDHC4.
• Evaluation of the combination therapy of oxamate and phenformin.

Main Results:

• Oxamate demonstrated inhibitory effects on the growth of invasive pituitary adenomas, medulloblastomas, and glioblastomas.
• Oxamate enhanced the sensitivity of glioblastomas to temozolomide and radiotherapy.
• Oxamate combination with phenformin exhibited synergistic anticancer efficacy and mitigated phenformin-induced lactic acidosis.
• Nanoliposomes were proposed to overcome oxamate's low cell penetrance.

Conclusions:

• Oxamate is a promising agent for slowing aggressive cancer progression, particularly brain tumors, by targeting LDHA and inducing mitochondrial apoptosis.
• Combination therapy with phenformin offers enhanced anticancer efficacy and improved safety profile.
• Further development, potentially using nanoliposomes or analogs, could optimize oxamate's clinical utility.